Morphocell Technologies Inc. successfully completed a $50 million Series A funding round, led by CDP Venture Capital and Investissement Québec, to advance innovative tissue therapies for liver diseases.

Target Company Overview

Morphocell Technologies Inc. is an innovative biotechnology company focused on developing next-generation tissue therapies aimed at replacing the functions of damaged organs. The company recently completed a $50 million Series A funding round, which included a $10 million increase in the investor syndicate led by CDP Venture Capital and Investissement Québec, the primary economic development agency of the Canadian province. This strategic addition complements the previous Series A funding of $40 million closed in February 2024, which was led by Genson Capital, and marks a significant milestone in Morphocell's journey towards transforming the treatment of liver diseases.

The involvement of such prominent institutional investors, both with a long-term vision and strategic mandates, further solidifies the company's growth foundations and extends its operational capacity by over three years.

Industry Overview in Canada

The life sciences industry in Canada, particularly in Quebec, is rapidly evolving and becoming a global hub for innovation and expertise. Quebec is home to a diverse array of biotechnology firms and research institutions, making it